You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

38 Results
Guidelines and Advice
Status: Current
ID: GL END 5-7
Version: 3
Nov 2021
Drug
Other Name(s): Vidaza®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Drug
Other Name(s): Arimidex®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025
Drug
Other Name(s): Alecensaro®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Drug
Other Name(s): Tecentriq™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    alectinib - Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer, according to criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
alectinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Skin, 
Merkel Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Avelumab - Metastatic Merkel Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
avelumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
Exceptional Access Program
    tretinoin (ATRA)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
tretinoin (ATRA),
arsenic trioxide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
Exceptional Access Program
    tretinoin (ATRA)
New Drug Funding Program
    Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
New Drug Funding Program
    Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
tretinoin (ATRA),
arsenic trioxide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Promyelocytic (APL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative, Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    methotrexate - oral tablets
Exceptional Access Program
    tretinoin (ATRA)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
tretinoin (ATRA),
mercaptopurine,
methotrexate
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2021
Drug
Other Name(s): Bavencio™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
atezolizumab,
atezolizumab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025

Pages